However, research has shown that most tumors have immune inhibitory mechanisms that limit the effectiveness of immunotherapy, including PD-1 expression on tumor-infiltrating T cells and the accumulation of inhibitory T cells, such as CD4+Foxp3+ regulatory T (Treg) cells, in the tumor microenvironment, which hinders anti-tumor immune responses. This evidence concerns the gene FOXP3 and neoplasm.